Checkpoint Therapeutics (NASDAQ:CKPT) Posts Earnings Results, Misses Estimates By $0.47 EPS

Checkpoint Therapeutics (NASDAQ:CKPT) issued its quarterly earnings results on Friday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.47), Zacks reports.

Checkpoint Therapeutics Trading Up 0.2 %

Shares of NASDAQ CKPT traded up $0.01 during mid-day trading on Friday, reaching $4.04. 522,554 shares of the company’s stock were exchanged, compared to its average volume of 1,124,079. The business has a fifty day simple moving average of $3.32 and a 200 day simple moving average of $3.25. Checkpoint Therapeutics has a twelve month low of $1.38 and a twelve month high of $4.50. The firm has a market capitalization of $197.29 million, a price-to-earnings ratio of -2.20 and a beta of 1.41.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CKPT. D. Boral Capital restated a “buy” rating and set a $4.80 target price (down from $9.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. HC Wainwright restated a “neutral” rating and set a $4.10 target price on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th. Finally, Lake Street Capital restated a “hold” rating and set a $4.10 target price (down from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th.

Insiders Place Their Bets

In other news, CFO William Garrett Gray sold 74,110 shares of the firm’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $3.67, for a total transaction of $271,983.70. Following the completion of the transaction, the chief financial officer now directly owns 1,458,644 shares of the company’s stock, valued at $5,353,223.48. This trade represents a 4.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO James F. Oliviero III sold 10,331 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $3.15, for a total transaction of $32,542.65. Following the transaction, the chief executive officer now owns 3,775,019 shares of the company’s stock, valued at $11,891,309.85. The trade was a 0.27 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 93,674 shares of company stock worth $336,011. Company insiders own 2.10% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.